Health-care providers can use the summary table as a quick reference guide to the classifications for hormonal contraceptive methods and intrauterine contraception and to compare classifications across these methods. See the full appendix for each method for clarifications to the numeric categories, as well as for summaries of the evidence and additional comments.
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.
Appendix L
Summary of Classifications for Hormonal Contraceptive Methods and Intrauterine Devices
TABLE. (Continued) Summary of classifications for hormonal contraceptive methods and intrauterine devices* |
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Condition |
COC/P/R |
POP |
DMPA |
Implants |
LNG-IUD |
Cu-IUD |
|||||||||
Obesity |
|||||||||||||||
a. ≥30 kg/m2 BMI |
2 |
1 |
1 |
1 |
1 |
1 |
|||||||||
b. Menarche to <18 yrs and ≥30 kg/m2 BMI |
2 |
1 |
2 |
1 |
1 |
1 |
|||||||||
History of bariatric surgery§ |
|||||||||||||||
a. Restrictive procedures: decrease storage capacity of the stomach (vertical banded gastroplasty, laparoscopic adjustable gastric band, laparoscopic sleeve gastrectomy) |
1 |
1 |
1 |
1 |
1 |
1 |
|||||||||
b. Malabsorptive procedures: decrease absorption of nutrients and calories by shortening the functional length of the small intestine (Roux-en-Y gastric bypass, biliopancreatic diversion) |
COCs: 3 P/R: 1 |
3 |
1 |
1 |
1 |
1 |
|||||||||
Cardiovascular Disease |
|||||||||||||||
Multiple risk factors for arterial cardiovascular disease (such as older age, smoking, diabetes, and hypertension) |
3/4† |
2† |
3† |
2† |
2 |
1 |
|||||||||
Hypertension |
|||||||||||||||
a. Adequately controlled hypertension |
3† |
1† |
2† |
1† |
1 |
1 |
|||||||||
b. Elevated blood pressure levels (properly taken measurements) |
|||||||||||||||
i. Systolic 140--159 mm Hg or diastolic 90--99 mm Hg |
3 |
1 |
2 |
1 |
1 |
1 |
|||||||||
ii. Systolic ≥160 mm Hg or diastolic ≥100 mm Hg§ |
4 |
2 |
3 |
2 |
2 |
1 |
|||||||||
c. Vascular disease |
4 |
2 |
3 |
2 |
2 |
1 |
|||||||||
History of high blood pressure during pregnancy (where current blood pressure is measurable and normal) |
2 |
1 |
1 |
1 |
1 |
1 |
|||||||||
Deep venous thrombosis (DVT)/ pulmonary embolism (PE) |
|||||||||||||||
a. History of DVT/PE, not on anticoagulant therapy |
|||||||||||||||
i. Higher risk for recurrent DVT/PE (≥1 risk factors) |
4 |
2 |
2 |
2 |
2 |
1 |
|||||||||
• History of estrogen-associated DVT/PE • Pregnancy-associated DVT/PE • Idiopathic DVT/PE • Known thrombophilia, including antiphospholipid syndrome • Active cancer (metastatic, on therapy, or within 6 mos after clinical remission), excluding non-melanoma skin cancer • History of recurrent DVT/PE |
|||||||||||||||
ii. Lower risk for recurrent DVT/PE (no risk factors) |
3 |
2 |
2 |
2 |
2 |
1 |
|||||||||
b. Acute DVT/PE |
4 |
2 |
2 |
2 |
2 |
2 |
|||||||||
c. DVT/PE and established on anticoagulant therapy for at least 3 mos |
|||||||||||||||
i. Higher risk for recurrent DVT/PE (≥1 risk factors) |
4† |
2 |
2 |
2 |
2 |
2 |
|||||||||
• Known thrombophilia, including antiphospholipid syndrome • Active cancer (metastatic, on therapy, or within 6 mos after clinical remission), excluding non-melanoma skin cancer • History of recurrent DVT/PE |
|||||||||||||||
ii. Lower risk for recurrent DVT/PE (no risk factors) |
3† |
2 |
2 |
2 |
2 |
2 |
TABLE. (Continued) Summary of classifications for hormonal contraceptive methods and intrauterine devices* |
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Condition |
COC/P/R |
POP |
DMPA |
Implants |
LNG-IUD |
Cu-IUD |
|||||||||
d. Family history (first-degree relatives) |
2 |
1 |
1 |
1 |
1 |
1 |
|||||||||
e. Major surgery |
|||||||||||||||
i. With prolonged immobilization |
4 |
2 |
2 |
2 |
2 |
1 |
|||||||||
ii. Without prolonged immobilization |
2 |
1 |
1 |
1 |
1 |
1 |
|||||||||
f. Minor surgery without immobilization |
1 |
1 |
1 |
1 |
1 |
1 |
|||||||||
Known thrombogenic mutations§ (e.g. factor V Leiden; prothrombin mutation; protein S, protein C, and antithrombin deficiencies) |
4† |
2† |
2† |
2† |
2† |
1† |
|||||||||
Superficial venous thrombosis |
|||||||||||||||
a. Varicose veins |
1 |
1 |
1 |
1 |
1 |
1 |
|||||||||
b. Superficial thrombophlebitis |
2 |
1 |
1 |
1 |
1 |
1 |
|||||||||
Current and history of ischemic heart disease§ |
Initiation |
Continuation |
Initiation |
Continuation |
Initiation |
Continuation |
|||||||||
4 |
2 |
3 |
3 |
2 |
3 |
2 |
3 |
1 |
|||||||
Stroke§ (history of cerebrovascular accident) |
Initiation |
Continuation |
Initiation |
Continuation |
|||||||||||
4 |
2 |
3 |
3 |
2 |
3 |
2 |
1 |
||||||||
Known hyperlipidemias |
2/3† |
2† |
2† |
2† |
2† |
1† |
|||||||||
Valvular heart disease |
|||||||||||||||
a. Uncomplicated |
2 |
1 |
1 |
1 |
1 |
1 |
|||||||||
b. Complicated§ (pulmonary hypertension, risk for atrial fibrillation, history of subacute bacterial endocarditis) |
4 |
1 |
1 |
1 |
1 |
1 |
|||||||||
Peripartum cardiomyopathy§ |
|||||||||||||||
a. Normal or mildly impaired cardiac function (New York Heart Association Functional Class I or II: patients with no limitation of activities or patients with slight, mild limitation of activity) (1) |
|||||||||||||||
i. <6 mos |
4 |
1 |
1 |
1 |
2 |
2 |
|||||||||
ii. ≥6 mos |
3 |
1 |
1 |
1 |
2 |
2 |
|||||||||
b. Moderately or severely impaired cardiac function (New York Heart Association Functional Class III or IV: patients with marked limitation of activity or patients who should be at complete rest) (1) |
4 |
2 |
2 |
2 |
2 |
2 |
|||||||||
Rheumatic Diseases |
|||||||||||||||
Systemic lupus erythematosus§ |
Initiation |
Continuation |
Initiation |
Continuation |
|||||||||||
a. Positive (or unknown) antiphospholipid antibodies |
4 |
3 |
3 |
3 |
3 |
3 |
1 |
1 |
|||||||
b. Severe thrombocytopenia |
2 |
2 |
3 |
2 |
2 |
2† |
3† |
2† |
|||||||
c. Immunosuppressive treatment |
2 |
2 |
2 |
2 |
2 |
2 |
2 |
1 |
|||||||
d. None of the above |
2 |
2 |
2 |
2 |
2 |
2 |
1 |
1 |
|||||||
Rheumatoid arthritis |
Initiation |
Continuation |
Initiation |
Continuation |
|||||||||||
a. On immunosuppressive therapy |
2 |
1 |
2/3† |
1 |
2 |
1 |
2 |
1 |
|||||||
b. Not on immunosuppressive therapy |
2 |
1 |
2 |
1 |
1 |
1 |
|||||||||
Neurologic Conditions |
|||||||||||||||
Headaches |
Initiation |
Continuation |
Initiation |
Continuation |
Initiation |
Continuation |
Initiation |
Continuation |
Initiation |
Continuation |
|||||
a. Non-migrainous (mild or severe) |
1† |
2† |
1† |
1† |
1† |
1† |
1† |
1† |
1† |
1† |
1† |
||||
b. Migraine |
|||||||||||||||
i. Without aura |
|||||||||||||||
• Age <35 yrs |
2† |
3† |
1† |
2† |
2† |
2† |
2† |
2† |
2† |
2† |
1† |
||||
• Age ≥35 yrs |
3† |
4† |
1† |
2† |
2† |
2† |
2† |
2† |
2† |
2† |
1† |
||||
ii. With aura (at any age) |
4† |
4† |
2† |
3† |
2† |
3† |
2† |
3† |
2† |
3† |
1† |
||||
Epilepsy§ |
1† |
1† |
1† |
1† |
1 |
1 |
|||||||||
If on treatment, see Drug Interactions section below |
TABLE. (Continued) Summary of classifications for hormonal contraceptive methods and intrauterine devices* |
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Condition |
COC/P/R |
POP |
DMPA |
Implants |
LNG-IUD |
Cu-IUD |
|||||||||
Depressive Disorders |
|||||||||||||||
Depressive disorders |
1† |
1† |
1† |
1† |
1† |
1† |
|||||||||
Reproductive Tract Infections and Disorders |
|||||||||||||||
Vaginal bleeding patterns |
Initiation |
Continuation |
|||||||||||||
a. Irregular pattern without heavy bleeding |
1 |
2 |
2 |
2 |
1 |
1 |
1 |
||||||||
b. Heavy or prolonged bleeding (includes regular and irregular patterns) |
1† |
2† |
2† |
2† |
1† |
2† |
2† |
||||||||
Unexplained vaginal bleeding (suspicious for serious condition) |
Initiation |
Continuation |
Initiation |
Continuation |
|||||||||||
Before evaluation |
2† |
2† |
3† |
3† |
4† |
2† |
4† |
2† |
|||||||
Endometriosis |
1 |
1 |
1 |
1 |
1 |
2 |
|||||||||
Benign ovarian tumors (including cysts) |
1 |
1 |
1 |
1 |
1 |
1 |
|||||||||
Severe dysmenorrhea |
1 |
1 |
1 |
1 |
1 |
2 |
|||||||||
Gestational trophoblastic disease |
|||||||||||||||
a. Decreasing or undetectable ß-hCG levels |
1 |
1 |
1 |
1 |
3 |
3 |
|||||||||
b. Persistently elevated ß-hCG levels or malignant disease§ |
1 |
1 |
1 |
1 |
4 |
4 |
|||||||||
Cervical ectropion |
1 |
1 |
1 |
1 |
1 |
1 |
|||||||||
Cervical intraepithelial neoplasia |
2 |
1 |
2 |
2 |
2 |
1 |
|||||||||
Cervical cancer (awaiting treatment) |
Initiation |
Continuation |
Initiation |
Continuation |
|||||||||||
2 |
1 |
2 |
2 |
4 |
2 |
4 |
2 |
||||||||
Breast disease |
|||||||||||||||
a. Undiagnosed mass |
2† |
2† |
2† |
2† |
2 |
1 |
|||||||||
b. Benign breast disease |
1 |
1 |
1 |
1 |
1 |
1 |
|||||||||
c. Family history of cancer |
1 |
1 |
1 |
1 |
1 |
1 |
|||||||||
d. Breast cancer§ |
|||||||||||||||
i. Current |
4 |
4 |
4 |
4 |
4 |
1 |
|||||||||
ii. Past and no evidence of current disease for 5 yrs |
3 |
3 |
3 |
3 |
3 |
1 |
|||||||||
Endometrial hyperplasia |
1 |
1 |
1 |
1 |
1 |
1 |
|||||||||
Endometrial cancer§ |
Initiation |
Continuation |
Initiation |
Continuation |
|||||||||||
1 |
1 |
1 |
1 |
4 |
2 |
4 |
2 |
||||||||
Ovarian cancer§ |
1 |
1 |
1 |
1 |
1 |
1 |
|||||||||
Uterine fibroids |
1 |
1 |
1 |
1 |
2 |
2 |
|||||||||
Anatomical abnormalities |
|||||||||||||||
a. Distorted uterine cavity (any congenital or acquired uterine abnormality distorting the uterine cavity in a manner that is incompatible with IUD insertion) |
4 |
4 |
|||||||||||||
b. Other abnormalities (including cervical stenosis or cervical lacerations) not distorting the uterine cavity or interfering with IUD insertion |
2 |
2 |
|||||||||||||
Pelvic inflammatory disease (PID) |
|||||||||||||||
a. Past PID (assuming no current risk factors of STIs) |
|||||||||||||||
Initiation |
Continuation |
Initiation |
Continuation |
||||||||||||
i. With subsequent pregnancy |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
|||||||
ii. Without subsequent pregnancy |
1 |
1 |
1 |
1 |
2 |
2 |
2 |
2 |
|||||||
b. Current PID |
1 |
1 |
1 |
1 |
4 |
2† |
4 |
2† |
TABLE. (Continued) Summary of classifications for hormonal contraceptive methods and intrauterine devices* |
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Condition |
COC/P/R |
POP |
DMPA |
Implants |
LNG-IUD |
Cu-IUD |
|||||||||
STIs |
Initiation |
Continuation |
Initiation |
Continuation |
|||||||||||
a. Current purulent cervicitis or chlamydial infection or gonorrhea |
1 |
1 |
1 |
1 |
4 |
2† |
4 |
2† |
|||||||
b. Other STIs (excluding HIV and hepatitis) |
1 |
1 |
1 |
1 |
2 |
2 |
2 |
2 |
|||||||
c. Vaginitis (including Trichomonas vaginalis and bacterial vaginosis) |
1 |
1 |
1 |
1 |
2 |
2 |
2 |
2 |
|||||||
d. Increased risk for STIs |
1 |
1 |
1 |
1 |
2/3† |
2 |
2/3† |
2 |
|||||||
HIV/AIDS |
|||||||||||||||
Initiation |
Continuation |
Initiation |
Continuation |
||||||||||||
High risk for HIV |
1 |
1 |
1 |
1 |
2 |
2 |
2 |
2 |
|||||||
HIV infection§ |
1 |
1 |
1 |
1 |
2 |
2 |
2 |
2 |
|||||||
AIDS§ |
1† |
1† |
1† |
1† |
3 |
2† |
3 |
2† |
|||||||
Clinically well on ARV therapy |
If on treatment, see Drug Interactions section below |
2 |
2 |
2 |
2 |
||||||||||
Other Infections |
|||||||||||||||
Schistosomiasis |
|||||||||||||||
a. Uncomplicated |
1 |
1 |
1 |
1 |
1 |
1 |
|||||||||
b. Fibrosis of the liver (if severe, see Cirrhosis)§ |
1 |
1 |
1 |
1 |
1 |
1 |
|||||||||
Tuberculosis§ |
Initiation |
Continuation |
Initiation |
Continuation |
|||||||||||
a. Nonpelvic |
1† |
1† |
1† |
1† |
1 |
1 |
1 |
1 |
|||||||
b. Pelvic |
1† |
1† |
1† |
1† |
4 |
3 |
4 |
3 |
|||||||
If on treatment, see Drug Interactions section below |
|||||||||||||||
Malaria |
1 |
1 |
1 |
1 |
1 |
1 |
|||||||||
Endocrine Conditions |
|||||||||||||||
Diabetes |
|||||||||||||||
a. History of gestational disease |
1 |
1 |
1 |
1 |
1 |
1 |
|||||||||
b. Nonvascular disease |
|||||||||||||||
i. Noninsulin-dependent |
2 |
2 |
2 |
2 |
2 |
1 |
|||||||||
ii. Insulin-dependent§ |
2 |
2 |
2 |
2 |
2 |
1 |
|||||||||
c. Nephropathy/retinopathy/neuropathy§ |
3/4† |
2 |
3 |
2 |
2 |
1 |
|||||||||
d. Other vascular disease or diabetes of >20 yrs' duration§ |
3/4† |
2 |
3 |
2 |
2 |
1 |
|||||||||
Thyroid disorders |
|||||||||||||||
a. Simple goiter |
1 |
1 |
1 |
1 |
1 |
1 |
|||||||||
b. Hyperthyroid |
1 |
1 |
1 |
1 |
1 |
1 |
|||||||||
c. Hypothyroid |
1 |
1 |
1 |
1 |
1 |
1 |
|||||||||
Gastrointestinal Conditions |
|||||||||||||||
Inflammatory bowel disease (IBD)(ulcerative colitis, Crohn disease) |
2/3† |
2 |
2 |
1 |
1 |
1 |
|||||||||
Gallbladder disease |
|||||||||||||||
a. Symptomatic |
|||||||||||||||
i. Treated by cholecystectomy |
2 |
2 |
2 |
2 |
2 |
1 |
|||||||||
ii. Medically treated |
3 |
2 |
2 |
2 |
2 |
1 |
|||||||||
iii. Current |
3 |
2 |
2 |
2 |
2 |
1 |
|||||||||
b. Asymptomatic |
2 |
2 |
2 |
2 |
2 |
1 |
|||||||||
History of cholestasis |
|||||||||||||||
a. Pregnancy-related |
2 |
1 |
1 |
1 |
1 |
1 |
|||||||||
b. Past COC-related |
3 |
2 |
2 |
2 |
2 |
1 |
|||||||||
Viral hepatitis |
Initiation |
Continuation |
|||||||||||||
a. Acute or flare |
3/4† |
2 |
1 |
1 |
1 |
1 |
1 |
||||||||
b. Carrier |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
||||||||
c. Chronic |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
||||||||
Cirrhosis |
|||||||||||||||
a. Mild (compensated) |
1 |
1 |
1 |
1 |
1 |
1 |
|||||||||
b. Severe§ (decompensated) |
4 |
3 |
3 |
3 |
3 |
1 |
TABLE. (Continued) Summary of classifications for hormonal contraceptive methods and intrauterine devices* |
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Condition |
COC/P/R |
POP |
DMPA |
Implants |
LNG-IUD |
Cu-IUD |
|||||||||
Liver tumors |
|||||||||||||||
a. Benign |
|||||||||||||||
i. Focal nodular hyperplasia |
2 |
2 |
2 |
2 |
2 |
1 |
|||||||||
ii. Hepatocellular adenoma§ |
4 |
3 |
3 |
3 |
3 |
1 |
|||||||||
b. Malignant§ (hepatoma) |
4 |
3 |
3 |
3 |
3 |
1 |
|||||||||
Anemias |
|||||||||||||||
Thalassemia |
1 |
1 |
1 |
1 |
1 |
2 |
|||||||||
Sickle cell disease§ |
2 |
1 |
1 |
1 |
1 |
2 |
|||||||||
Iron-deficiency anemia |
1 |
1 |
1 |
1 |
1 |
2 |
|||||||||
Solid Organ Transplantation |
|||||||||||||||
Solid organ transplantation§ |
Initiation |
Continuation |
Initiation |
Continuation |
|||||||||||
a. Complicated: graft failure (acute or chronic), rejection, cardiac allograft vasculopathy |
4 |
2 |
2 |
2 |
3 |
2 |
3 |
2 |
|||||||
b. Uncomplicated |
2† |
2 |
2 |
2 |
2 |
2 |
|||||||||
Drug Interactions |
|||||||||||||||
Antiretroviral therapy (see appendix M) |
Initiation |
Continuation |
Initiation |
Continuation |
|||||||||||
a. Nucleoside reverse transcriptase inhibitors (NRTIs) |
1† |
1 |
1 |
1 |
2/3† |
2† |
2/3† |
2† |
|||||||
b. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) |
2† |
2† |
1 |
2† |
2/3† |
2† |
2/3† |
2† |
|||||||
c. Ritonavir-boosted protease inhibitors |
3† |
3† |
1 |
2† |
2/3† |
2† |
2/3† |
2† |
|||||||
Anticonvulsant therapy |
|||||||||||||||
a. Certain anticonvulsants (phenytoin, carbamazepine, barbiturates, primidone, topiramate, oxcarbazepine) |
3† |
3† |
1 |
2† |
1 |
1 |
|||||||||
b. Lamotrigine |
3† |
1 |
1 |
1 |
1 |
1 |
|||||||||
Antimicrobial therapy |
|||||||||||||||
a. Broad-spectrum antibiotics |
1 |
1 |
1 |
1 |
1 |
1 |
|||||||||
b. Antifungals |
1 |
1 |
1 |
1 |
1 |
1 |
|||||||||
c. Antiparasitics |
1 |
1 |
1 |
1 |
1 |
1 |
|||||||||
d. Rifampicin or rifabutin therapy |
3† |
3† |
1 |
2† |
1 |
1 |
|||||||||
* Abbreviations: COC = combined oral contraceptive; P = combined hormonal contraceptive patch; R = combined hormonal vaginal ring; POP = progestin-only pill; DMPA = depot medroxyprogesterone acetate; IUD = intrauterine device; LNG-IUD = levonorgestrel-releasing IUD; Cu-IUD = copper IUD; BMI = body mass index; DVT = deep venous thrombosis; PE = pulmonary embolism; hCG, = human chorionic gonadotropin; PID = pelvic inflammatory disease; STI = sexually transmitted infection; HIV = human immunodeficiency virus; AIDS = acquired immunodeficiency syndrome; NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = non-nucleoside reverse transcriptase. † Consult the appendix for this contraceptive method for a clarification to this classification. § Condition that exposes a woman to increased risk as a result of unintended pregnancy. |
Reference
- The Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. Boston, MA: Little, Brown & Co.; 1994.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.
References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
All MMWR HTML versions of articles are electronic conversions from typeset documents.
This conversion might result in character translation or format errors in the HTML version.
Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr)
and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S.
Government Printing Office (GPO), Washington, DC 20402-9371;
telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to
mmwrq@cdc.gov.